ADC Therapeutics (NYSE:ADCT – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Guggenheim in a research note issued on Friday, Benzinga reports. Other research analysts have also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective on shares of […]
ADC Therapeutics (NYSE:ADCT – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a note issued to investors on Friday, Benzinga reports. Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on […]
ADC Therapeutics SA (NYSE:ADCT – Get Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,360,000 shares, a drop of 9.7% from the December 31st total of 3,720,000 shares. Approximately 6.2% of the shares of the stock are […]
ADC Therapeutics SA (NYSE:ADCT – Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 3,360,000 shares, a decrease of 9.7% from the December 31st total of 3,720,000 shares. Approximately 6.2% of the shares of the company are […]
Shares of ADC Therapeutics SA (NYSE:ADCT – Get Free Report) have earned an average recommendation of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy […]